BioLineRX
BLRX
29 hedge funds and large institutions have $6.69M invested in BioLineRX in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
67% more capital invested
Capital invested by funds: $4.01M → $6.69M (+$2.67M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
4% more funds holding
Funds holding: 28 → 29 (+1)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
97% less call options, than puts
Call options by funds: $13K | Put options by funds: $408K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.19M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$356K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$230K |
| 4 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$227K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$958K |
| 2 |
Renaissance Technologies
New York
|
-$180K |
| 3 |
VF
Virtu Financial
New York
|
-$47K |
| 4 |
Millennium Management
New York
|
-$42K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
-$35.6K |
BLRX Hedge Fund Activity: Q3 2021 in Review
29 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2021, worth a combined $6.69M — up 67% from $4.01M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BLRX positions and 5 closed out — a net gain of 1 holder — while 6 added to existing stakes and 5 trimmed.
The largest buyer was ARK Investment Management, opening a new position worth an estimated $3.19M. The largest seller was Parkman Healthcare Partners, cutting an estimated $958K.
- 29 institutional investors held BioLineRX (BLRX) as of Q3 2021, up from 28 in Q2 2021.
- Funds reported $6.69M of BioLineRX stock for Q3 2021, up 67% quarter-over-quarter.
- 6 funds opened new BioLineRX positions in Q3 2021 and 5 closed out, a net change of +1 holder.
- The largest BioLineRX buyer in Q3 2021 was ARK Investment Management, an estimated $3.19M added.
- The largest BioLineRX seller in Q3 2021 was Parkman Healthcare Partners, an estimated $958K sold.
Based on aggregated 13F filings for Q3 2021.